Patent and proprietary medicine vendors in Nigeria play a very integral role in providing primary health care services and are an important source of care for the poor. They are located close to communities and are often the first source of care for hygiene and family planning (FP) products and treatment of child illnesses. Since 2017, Pharmacy Council of Nigeria (PCN) has partnered with Society for Family Health through the IntegratE project to address the poor quality of services by patent and proprietary medicine vendors (PPMVs) and reposition them for better service delivery through piloting the three-tier accreditation system. The partnership has engendered innovation for human resource for health, and considering the peculiarity of their situation, new emerging methods and arrangements to deliver the training to PPMVs in diverse geographical locations within their catchment areas are developed. In this study, we aimed to discuss the role of patent and proprietary medicine vendors in the provision of quality health delivery and provide key lessons and recommendations which have been learned from the pilot scaling of training facilities for PPMVs in Nigeria through the IntegratE project. From the lessons learnt, we propose that, for a successful scale-up of implementation of the three-tier accreditation of PPMVs, PCN will have to establish a budget line for accreditation. In addition, the government should also consider supporting this training through the Basic Healthcare Provision Fund as a way of strengthening human resources at the primary healthcare level. Other alternative sources of funding include licensing and registration fees and other dues generated internally by PCN.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11304711 | PMC |
http://dx.doi.org/10.1186/s12961-024-01186-8 | DOI Listing |
J Photochem Photobiol B
January 2025
Department of Ophthalmology, Aotearoa New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand. Electronic address:
Purpose: Preclinical studies have confirmed the safety and efficacy of narrowband low-intensity ultraviolet C light (UVC) in managing bacterial corneal infection. To further consolidate these findings, the present study aimed to explore in vitro anti-biofilm efficacy of low-intensity UVC light for its potential use in biofilm-related infections.
Methods: Pseudomonas aeruginosa biofilm was grown in chamber well slides for 48 h and exposed to one of the following challenges: UVC (265 nm wavelength, intensity 1.
Clin Cosmet Investig Dermatol
December 2024
Phio Pharmaceuticals, Marlborough, MA, USA.
Purpose: Abnormal melanin synthesis causes hyperpigmentation disorders like melasma and lentigines, impacting psychological well-being. RNA interference (RNAi) uses small RNA molecules to inhibit gene expression by targeting specific mRNA, silencing genes involved in undesirable cellular functions. This study assessed INTASYL compounds, self-delivering RNAi molecules, designed to target and reduce tyrosinase gene expression to decrease pigmentation.
View Article and Find Full Text PDFJ Affect Disord
December 2024
Compass Pathfinder Ltd (a subsidiary of Compass Pathways plc), London, UK.
Objective: To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression.
Methods: For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with psychological support.
Expert Opin Ther Pat
January 2025
Center for Therapeutics Discovery, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Introduction: WDR5 is an epigenetic scaffolding protein that has attracted significant interest as an anti-cancer drug target, especially in MLL-rearranged leukemias. The most druggable 'WIN-site' on WDR5, which tethers WDR5 to chromatin, has been successfully targeted with multiple classes of exquisitely potent small-molecule protein-protein interaction inhibitors. Earlier progress has also been made on the development of WDR5 degraders and inhibitors at the 'WBM-site' on the opposite face of WDR5.
View Article and Find Full Text PDFZhongguo Zhong Yao Za Zhi
October 2024
Department of Cardiovascular Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000, China.
Chinese patent medicines play a crucial role in the treatment of chronic pulmonary heart disease(CPHD). Nowadays, there is still a lack of comprehensive control over clinical research evidence in this field. This study aims to summarize the clinical research on the treatment of CPHD with Chinese patent medicines using an evidence map, in order to understand the current status and deficiencies of evidence in this area.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!